RT Journal Article
T1 Detection methods predict differences in biology and survival in breast cancer patients
A1 Redondo-Bautista, Maximino
A1 Funez, Rafael
A1 Medina Cano, Francisco José
A1 Rodrigo, Isabel
A1 Acebal-Blanco, María Mercedes
A1 Téllez-Santana, Teresa
A1 Roldán Cardenete, María José
A1 Hortas Nieto, María Luisa
A1 Bellinvia, Ana
A1 Pereda, Teresa
A1 Domingo, Laia
A1 Morales-Suárez-Varela, María Manuela
A1 Sala, Maria
A1 Rueda-Domínguez, Antonio
K1 Mamas - Cáncer
AB Background: The aim of this study was to measure the biological characteristics involved in tumorigenesis and the progression of breast cancer in symptomatic and screen-detected carcinomas to identify possible differences.Methods: For this purpose, we evaluated clinical-pathological parameters and proliferative and apoptotic activities in a series of 130 symptomatic and 161 screen-detected tumors.Results: After adjustment for the smaller size of the screen-detected carcinomas compared with symptomatic cancers, those detected in the screening program presented longer disease-free survival (RR = 0.43, CI = 0.19-0.96) and had high estrogen and progesterone receptor concentrations more often than did symptomatic cancers (OR = 3.38, CI = 1.72-6.63 and OR = 3.44, CI = 1.94-6.10, respectively). Furthermore, the expression of bcl-2, a marker of good prognosis in breast cancer, was higher and HER2/neu expression was lower in screen-detected cancers than in symptomatic cancers (OR = 1.77, CI = 1.01-3.23 and OR = 0.64, CI = 0.40-0.98, respectively). However, when comparing prevalent vs incident screen-detected carcinomas, prevalent tumors were larger (OR = 2.84, CI = 1.05-7.69), were less likely to be HER2/neu positive (OR = 0.22, CI = 0.08-0.61) and presented lower Ki67 expression (OR = 0.36, CI = 0.17-0.77). In addition, incident tumors presented a shorter survival time than did prevalent ones (RR = 4.88, CI = 1.12-21.19).Conclusions: Incident carcinomas include a variety of screen-detected carcinomas that exhibit differences in biology and prognosis relative to prevalent carcinomas. The detection method is important and should be taken into account when making therapy decisions.
PB BMC Springer Nature
YR 2012
FD 2012
LK https://hdl.handle.net/10630/33639
UL https://hdl.handle.net/10630/33639
LA eng
NO Redondo M, Funez R, Medina-Cano F, Rodrigo I, Acebal M, Tellez T, Roldan MJ, Hortas ML, Bellinvia A, Pereda T, Domingo L, Morales-Suarez Varela M, Sala M, Rueda A. Detection methods predict differences in biology and survival in breast cancer patients. BMC Cancer. 2012 Dec 17;12:604. doi: 10.1186/1471-2407-12-604. PMID: 23244222; PMCID: PMC3541058.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 27 feb 2026